Armenia Medical Device Regulatory Overview 2026: EAEU Dual-Track Framework and Compliance Actions

1. Key takeaways

Medical device regulation in Armenia is not a single set of rules. It is a two-layer structure: the upper layer consists of the unified registration rules of the Eurasian Economic Union (EAEU), while the lower layer consists of the transitional arrangements preserved in Chapter 10 of the Armenian Law On Medical Assistance and Services to the Population. The GRZAN judgment is that registration follows the Union rules, while import and circulation follow the national transitional procedures, with the two tracks running in parallel until December 31, 2027. When planning a product for the Armenian market, companies must therefore prepare two complete documentation packages at the same time: the Union registration dossier and the national import (compliance) certificate file. Missing either package makes it impossible to close the commercial loop, because a registration certificate alone does not authorize import clearance, and an import certificate alone does not establish long-term market authorization.

2. Legal basis

3. Expert insights

Insight 1: the dual track is not a choice between two options but a sequence of stages. The Union rules answer the question of whether a product can be legally registered on the EAEU market, while the national transitional procedures answer the question of whether a product can be legally imported into and circulated in Armenia when registration has not yet been completed or does not yet apply. The two regimes operate on different stages of the life cycle of the same product, so there is no selection relationship between them, only a temporal sequence. A submission strategy that treats the tracks as alternatives will fail at either the registration stage or the customs stage.

Insight 2: the entry into force of the Agreement and of the implementing decisions are not synchronized. The Agreement of December 23, 2014 itself entered into force on February 12, 2016, while many implementing decisions tie their entry into force to a period of 10 or 30 calendar days from the day the Protocol on the Accession of the Republic of Armenia to that Agreement (signed on December 2, 2015) entered into force. GRZAN has verified Council Decisions No. 26, 27, 28, 29 and 42: the entry-into-force clauses of each state that they take effect 10 calendar days after the entry into force of the Protocol, and in no case earlier than 10 calendar days after official publication. This means that the accession of Armenia directly triggered the application of the entire body of implementing rules, which is a key milestone on the Armenian regulatory timeline.

Insight 3: Article 2 of Decision No. 46 was the original legal source of the transition period, but it has since been revised. The original version of Decision No. 46 set the transition period to end on December 31, 2021, and provided that registration documents issued under national rules of the member states would remain valid no later than that date. After the revision by Decision No. 144 of 2021, the rules were replaced as a whole, and the transitional arrangements were carried by the Agreement protocols and by national law of the member states. Armenian national law now sets the transition period explicitly to December 31, 2027. Companies that still calibrate their timelines to the end of 2021 will make incorrect scheduling judgments for their submissions.

4. Practical recommendations

1. Layer the requirements before acting: as the first step of project initiation, build a dual-track checklist that splits the product into Union registration requirements and Armenian import requirements in two columns, and assign an owner and a document source to every item.
2. Let national law govern transition-period judgments: for any question on whether an unregistered device may be imported, rely on Chapter 10 of the Armenian Law On Medical Assistance and Services to the Population and on Government Decision No. 429-Ն; do not borrow transition-period practical estimates from Russia or Kazakhstan.
3. Lock in the milestones: enter December 31, 2027 into the product compliance calendar and start a countdown review of Union registration 12 months before that date.
4. Keep official screenshots: Decision No. 429-Ն has already been amended twice (No. 1731-Ն in 2023 and No. 1619-Ն in 2024), so the current consolidated text must be retrieved from arlis.am before any submission; outdated annex lists must not be reused.

5. Verification checklist

1. □ It has been confirmed that the product falls within the definition of a medical device (including standalone software) in Chapter 10 of the Law On Medical Assistance and Services to the Population.
2. □ It has been confirmed that the intended pathway is Union registration or transitional-period import, and the basis of that judgment has been recorded in writing.
3. □ The current text of the Agreement of 2014-12-23 has been retrieved, and Article 3(2) and Article 4(2) and (4) have been checked.
4. □ The full text of Decision No. 46 (as revised in 2021) has been retrieved and the scope of application in Article 1 has been checked.
5. □ The current consolidated version of Decision No. 429-Ն (including the 2024 amendment) has been retrieved from arlis.am.
6. □ December 31, 2027 and the review point 12 months earlier have been marked in the product compliance calendar.
7. □ The triggering role of the Armenian accession Protocol (2015-12-02) in the regulatory chain of this product has been confirmed.

Regulatory information verified as of October 30, 2026.

GRZAN services. GRZAN International provides regulatory consulting for medical device manufacturers entering the Eurasian Economic Union and its member states, including Armenia. Our services cover EAEU registration strategy, national import and compliance certification, transition-period planning, and authorized representative support. For inquiries, contact info@grzanglobal.com.